At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Pirtobrutinib (drug)
- How long the study runs
- Study runs about 91 months (dates as stated)
- About the drug or intervention
- Pirtobrutinib — drug: Administered orally.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at the long-term safety of a medicine called pirtobrutinib (also known as LY3527727) in people with chronic lymphocytic leukaemia (a type of blood cancer) or non-Hodgkin lymphoma (a group of blood cancers). It is run by Eli Lilly and Company. The details of who can take part are set out in each individual study.
Who can take part
- You are already taking part in an eligible Lilly-sponsored clinical study of pirtobrutinib.
Who may not be able to
- Reasons you cannot take part are set out in each individual study — ask the trial team.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 787
- Started
- 2025-05-20
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for chronic lymphocytic leukemia
- • Phase4 - 787 participants
- • The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with chronic lymphocytic leukemia
Where?
- • Leeds - St James's University Hospital
- • Oxford - Churchill Hospital
- • Plymouth - Derriford Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Who cannot take part
- ✗Exclusion criteria are defined in each ISA.
See the full criteria
Where Is This Study? (3 UK sites)
St James's University Hospital
Leeds LS9 7TF, United Kingdom
Churchill Hospital
Oxford OX3 7LE, United Kingdom
Derriford Hospital
Plymouth PL6 8DH, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT